
Pubmed-entry ::= {
  pmid 29755131,
  medent {
    em std {
      year 2018,
      month 5,
      day 15,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "KMT2C mediates the estrogen dependence of breast cancer through
 regulation of ERalpha enhancer function."
      },
      authors {
        names std {
          {
            name ml "Gala K",
            affil str "Louis V. Gerstner, Jr. Graduate School of Biomedical
 Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center,
 New York, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Li Q",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Sinha A",
            affil str "Basepair, Inc, New York, USA."
          },
          {
            name ml "Razavi P",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Dorso M",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Sanchez-Vega F",
            affil str "Department of Medicine, Washington University School of
 Medicine, St. Louis, MO, USA."
          },
          {
            name ml "Chung YR",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Hendrickson R",
            affil str "Microchemistry and Proteomics Core Facility, Memorial
 Sloan Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Hsieh JJ",
            affil str "Department of Medicine, Washington University School of
 Medicine, St. Louis, MO, USA."
          },
          {
            name ml "Berger M",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Schultz N",
            affil str "Computational Biology Program, Memorial Sloan Kettering
 Cancer Center, New York, USA."
          },
          {
            name ml "Pastore A",
            affil str "Computational Biology Program, Memorial Sloan Kettering
 Cancer Center, New York, USA."
          },
          {
            name ml "Abdel-Wahab O",
            affil str "Human Oncology and Pathogenesis Program, Memorial Sloan
 Kettering Cancer Center, New York, USA."
          },
          {
            name ml "Chandarlapaty S",
            affil str "Louis V. Gerstner, Jr. Graduate School of Biomedical
 Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center,
 New York, USA. chandars@mskcc.org.; Human Oncology and Pathogenesis Program,
 Memorial Sloan Kettering Cancer Center, New York, USA. chandars@mskcc.org.;
 Weill Cornell Medical College, New York, USA. chandars@mskcc.org."
          }
        }
      },
      from journal {
        title {
          iso-jta "Oncogene",
          ml-jta "Oncogene",
          issn "1476-5594",
          name "Oncogene"
        },
        imp {
          date std {
            year 2018,
            month 8
          },
          volume "37",
          issue "34",
          pages "4692-4710",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus received,
              date std {
                year 2017,
                month 3,
                day 26
              }
            },
            {
              pubstatus accepted,
              date std {
                year 2018,
                month 3,
                day 28
              }
            },
            {
              pubstatus revised,
              date std {
                year 2018,
                month 1,
                day 30
              }
            },
            {
              pubstatus pubmed,
              date std {
                year 2018,
                month 5,
                day 15,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2019,
                month 2,
                day 28,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2018,
                month 5,
                day 15,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29755131,
        doi "10.1038/s41388-018-0273-5",
        pii "10.1038/s41388-018-0273-5",
        other {
          db "pmc",
          tag str "PMC6107480"
        },
        other {
          db "mid",
          tag str "NIHMS956042"
        },
        other {
          db "ELocationID doi",
          tag str "10.1038/s41388-018-0273-5"
        }
      }
    },
    abstract "Estrogen receptor alpha (ERalpha) is a ligand-activated nuclear
 receptor that directs proliferation and differentiation in selected cancer
 cell types including mammary-derived carcinomas. These master-regulatory
 functions of ERalpha require trans-acting elements such as the pioneer factor
 FOXA1 to establish a genomic landscape conducive to ERalpha control. Here, we
 identify the H3K4 methyltransferase KMT2C as necessary for hormone-driven
 ERalpha activity and breast cancer proliferation. KMT2C knockdown suppresses
 estrogen-dependent gene expression and causes H3K4me1 and H3K27ac loss
 selectively at ERalpha enhancers. Correspondingly, KMT2C loss impairs
 estrogen-driven breast cancer proliferation but has no effect on ER- breast
 cells. Whereas KMT2C loss disrupts estrogen-driven proliferation, it
 conversely promotes tumor outgrowth under hormone-depleted conditions. In
 accordance, KMT2C is one of the most frequently mutated genes in ER-positive
 breast cancer with KMT2C deletion correlating with significantly shorter
 progression-free survival on anti-estrogen therapy. From a therapeutic
 standpoint, KMT2C-depleted cells that develop hormone-independence retain
 their dependence on ERalpha, displaying ongoing sensitivity to ERalpha
 antagonists. We conclude that KMT2C is a key regulator of ERalpha activity
 whose loss uncouples breast cancer proliferation from hormone abundance.",
    mesh {
      {
        term "Animals"
      },
      {
        term "Breast Neoplasms",
        qual {
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Cell Line"
      },
      {
        term "Cell Line, Tumor"
      },
      {
        term "Cell Proliferation",
        qual {
          {
            subh "physiology"
          }
        }
      },
      {
        term "DNA-Binding Proteins",
        qual {
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Estrogen Receptor alpha",
        qual {
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Estrogens",
        qual {
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Female"
      },
      {
        term "Gene Expression Regulation, Neoplastic",
        qual {
          {
            subh "physiology"
          }
        }
      },
      {
        term "HEK293 Cells"
      },
      {
        term "Hepatocyte Nuclear Factor 3-alpha",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Humans"
      },
      {
        term "MCF-7 Cells"
      },
      {
        term "Mice"
      },
      {
        term "Mice, Inbred C57BL"
      },
      {
        term "Mice, Transgenic"
      },
      {
        term "Neoplasm Proteins",
        qual {
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Progression-Free Survival"
      },
      {
        term "Signal Transduction",
        qual {
          {
            subh "physiology"
          }
        }
      }
    },
    substance {
      {
        type nameonly,
        name "DNA-Binding Proteins"
      },
      {
        type nameonly,
        name "Estrogen Receptor alpha"
      },
      {
        type nameonly,
        name "Estrogens"
      },
      {
        type nameonly,
        name "Hepatocyte Nuclear Factor 3-alpha"
      },
      {
        type nameonly,
        name "KMT2D protein, human"
      },
      {
        type nameonly,
        name "Neoplasm Proteins"
      },
      {
        type nameonly,
        name "estrogen receptor alpha, human"
      }
    },
    idnum {
      "P30 CA008748/CA/NCI NIH HHS"
    },
    pmid 29755131,
    pub-type {
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    },
    status medline
  }
}


